UK markets closed

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
35.940.00 (0.00%)
At close: 11:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close35.94
Open36.60
Bid0.00 x 0
Ask0.00 x 0
Day's range35.94 - 35.94
52-week range21.14 - 43.97
Volume8
Avg. volume145
Market cap541.134M
Beta (5Y monthly)1.07
PE ratio (TTM)N/A
EPS (TTM)-3.08
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Abivax announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling eur 85m new financing

    DGAP-News: ABIVAX / Key word(s): Capital Increase/Issue of Debt23.07.2021 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling EUR 85m new financing EUR 60M reserved primary equity offering at minimum discount (3%) EUR 25M convertible bonds priced at 6.00% coupon and 25% conversion premium Proceeds to be primarily used for further advancement of ABX46

  • EQS Group

    Abivax capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80m

    DGAP-News: ABIVAX / Key word(s): Capital Increase22.07.2021 / 17:45 The issuer is solely responsible for the content of this announcement.Abivax capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80m PARIS, FRANCE, July 22, 2021 - 5:45 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory di

  • EQS Group

    Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis

    DGAP-News: ABIVAX / Key word(s): Study/Study results23.06.2021 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis Primary endpoint met with ABX464 demonstrating good safety and tolerability profile with 50mg once daily oral administration A statistically significant difference (p < 0.03) was met on key efficacy endpoint ACR20[1] in the PP[2] population with 6